AMTI Fundamental Analysis - APPLIED MOLECULAR TRANSPORT

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to AMTI. AMTI was compared to 540 industry peers in the Biotechnology industry. The financial health of AMTI is average, but there are quite some concerns on its profitability. AMTI does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

AMTI had negative earnings in the past year.

AMTI had a negative operating cash flow in the past year.

AMTI had negative earnings in each of the past 5 years.

AMTI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -373.95%, AMTI is doing worse than 97.30% of the companies in the same industry.

The Return On Equity of AMTI (-461.67%) is worse than 80.61% of its industry peers.

		Industry Rank	Sector Rank
ROA	-373.95%
ROE	-461.67%
ROIC	N/A

ROA(3y)-70.66%

ROA(5y)-82.71%

ROE(3y)-106.54%

ROE(5y)-110.95%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AMTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, AMTI has more shares outstanding

AMTI has a worse debt/assets ratio than last year.

2.2 Solvency

AMTI has an Altman-Z score of -36.49. This is a bad value and indicates that AMTI is not financially healthy and even has some risk of bankruptcy.

AMTI's Altman-Z score of -36.49 is on the low side compared to the rest of the industry. AMTI is outperformed by 94.94% of its industry peers.

AMTI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-36.49

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 4.95 indicates that AMTI has no problem at all paying its short term obligations.

AMTI's Current ratio of 4.95 is in line compared to the rest of the industry. AMTI outperforms 50.59% of its industry peers.

AMTI has a Quick Ratio of 4.95. This indicates that AMTI is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of AMTI (4.95) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.95
Quick Ratio	4.95

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.09% over the past year.

EPS 1Y (TTM)45.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%73.85%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

AMTI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.45% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y70.28%

EPS Next 2Y32.75%

EPS Next 3Y14.38%

EPS Next 5Y12.45%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMTI. In the last year negative earnings were reported.

Also next year AMTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AMTI's earnings are expected to grow with 14.38% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.75%

EPS Next 3Y14.38%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AMTI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

APPLIED MOLECULAR TRANSPORT

NASDAQ:AMTI (12/26/2023, 8:00:01 PM)

After market: 0.2629 0 (-0.04%)

0.263

-0.04 (-14.3%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-09 2023-11-09/amc

Earnings (Next)03-07 2024-03-07/amc

Inst Owners0%

Inst Owner Change0%

Ins Owners1.85%

Ins Owner Change0%

Market Cap11.01M

Analysts43.33

Price Target1.02 (287.83%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-44.68%

Min EPS beat(2)-156.02%

Max EPS beat(2)66.67%

EPS beat(4)2

Avg EPS beat(4)-25.3%

Min EPS beat(4)-156.02%

Max EPS beat(4)66.67%

EPS beat(8)3

Avg EPS beat(8)-21.97%

EPS beat(12)5

Avg EPS beat(12)-11.57%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.68
P/tB	0.68
EV/EBITDA	N/A

EPS(TTM)-1.9

EYN/A

EPS(NY)-0.78

Fwd EYN/A

FCF(TTM)-1.45

FCFYN/A

OCF(TTM)-1.43

OCFYN/A

SpS0

BVpS0.39

TBVpS0.39

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-373.95%
ROE	-461.67%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-70.66%

ROA(5y)-82.71%

ROE(3y)-106.54%

ROE(5y)-110.95%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	30%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.95
Quick Ratio	4.95
Altman-Z	-36.49

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)159.65%

Cap/Depr(5y)173.81%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)45.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%73.85%

EPS Next Y70.28%

EPS Next 2Y32.75%

EPS Next 3Y14.38%

EPS Next 5Y12.45%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y55.72%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year53.67%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y23.33%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y21.85%

OCF growth 3YN/A

OCF growth 5YN/A

APPLIED MOLECULAR TRANSPORT (AMTI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens